Scienture Holdings Inc (SCNX)

$0.96 -0.02 (-2.32%)
Market Cap 20.39M
Revenue (ttm) 140,000.00
Net Income (ttm) 9.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 6,478.57%
Debt to Equity Ratio 0.01
Volume 4,543,900
Avg Vol 387,578
Day's Range N/A - N/A
Shares Out 20.75M
Stochastic %K 40%
Beta 3.06
Analysts Strong Buy
Price Target N/A

Company Profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN...

Industry: Pharmaceutical Retailers
Sector: Healthcare
Phone: 800 261 0281
Address:
6308 Benjamin Rd, Suite 708, Tampa, United States
Moneymastermind99
Moneymastermind99 Sep. 17 at 2:55 AM
$TGL Update 🚀 Closed strong above key support ~$1.09–1.15, holding trend shift. Next resistance at ~$1.18–1.20, then $1.40–1.50. Breakout on volume could target $2–$2.50+ (52 week high $76.50) Float is tiny (~3.7M), so even small buys/sells move price fast. Indicators (MACD + short MAs) flipping bullish, though long-term trend still weak. Catalysts: AI/cloud expansion via ZCITY, Mezzofy digital coupon partnership, crypto/digital treasury buildout. Risk: If $1.09 breaks, watch $1.00 or lower. Volatility extreme. Similar low-float names: $ADAP $SCNX $IXHL #TGL #Stocks #LowFloat #AI #Momentum #DayTrading
0 · Reply
Bigcat85
Bigcat85 Sep. 17 at 1:29 AM
$SCNX shocker, good news and in the red!
0 · Reply
Jhc1114
Jhc1114 Sep. 17 at 12:43 AM
$SCNX S-3 424B3 FUCK YOU CURRY
0 · Reply
Moneymastermind99
Moneymastermind99 Sep. 16 at 10:03 PM
$TGL Strong Close 🚀 Tiny float = huge volatility. Even small buys/sells move it fast. Closed strong above support ~$1.15 with eyes on $1.40-$1.50 resistance. Breakout on volume could target $2-$3 near term. Risky but explosive setup. 🔥 Similar low-float plays to watch: $ADAP $SCNX $IXHL #TGL #Stocks #LowFloat #Momentum #DayTrading #PennyStocks
0 · Reply
Risktaking
Risktaking Sep. 16 at 6:34 PM
$SCNX Looks more like a squeeze downward. She might be cooked
1 · Reply
Adam_85
Adam_85 Sep. 16 at 5:56 PM
$SCNX Go baby Go
0 · Reply
MakeM0ney_444
MakeM0ney_444 Sep. 16 at 5:23 PM
$SCNX this is being suppressed isn’t it
1 · Reply
MMstockm
MMstockm Sep. 16 at 5:20 PM
$SCNX loading
0 · Reply
Dabstunts
Dabstunts Sep. 16 at 4:58 PM
$SCNX they just stole your shares at .93.....now ready to move! Hold on...
0 · Reply
The_Rocketstock
The_Rocketstock Sep. 16 at 4:57 PM
$SCNX come on,lets do it.
0 · Reply
Latest News on SCNX
SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Sep 16, 2025, 8:05 AM EDT - 16 hours ago

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Aug 14, 2025, 9:00 AM EDT - 4 weeks ago

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Aug 13, 2025, 8:05 AM EDT - 4 weeks ago

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Jul 24, 2025, 5:12 PM EDT - 7 weeks ago

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Jul 16, 2025, 8:15 AM EDT - 2 months ago

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Scienture Holdings Announces Cancelation of ELOC

Jun 17, 2025, 8:05 AM EDT - 3 months ago

Scienture Holdings Announces Cancelation of ELOC

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

May 28, 2025, 7:45 AM EDT - 3 months ago

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

WGRX

SCIENTURE Announces Executive Leadership Transition

May 22, 2025, 8:05 AM EDT - 4 months ago

SCIENTURE Announces Executive Leadership Transition

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

May 19, 2025, 8:05 AM EDT - 4 months ago

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Apr 22, 2025, 8:05 AM EDT - 5 months ago

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Apr 8, 2025, 8:05 AM EDT - 5 months ago

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Apr 3, 2025, 8:26 AM EDT - 5 months ago

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Mar 25, 2025, 8:05 AM EDT - 6 months ago

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

Mar 19, 2025, 8:05 AM EDT - 6 months ago

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

Mar 18, 2025, 8:05 AM EDT - 6 months ago

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Mar 6, 2025, 7:40 AM EST - 6 months ago

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Jan 21, 2025, 8:05 AM EST - 8 months ago

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Dec 17, 2024, 8:05 AM EST - 9 months ago

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

Dec 10, 2024, 8:05 AM EST - 10 months ago

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

Sep 24, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

Sep 20, 2024, 11:59 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

Aug 5, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

Jul 26, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

TRxADE Health, Inc. Announces Special Cash Dividend

Jul 9, 2024, 8:05 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Special Cash Dividend

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

May 29, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Apr 23, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Trxade health, Inc files its 3Q 10Q

Jan 17, 2024, 9:07 AM EST - 1 year ago

Trxade health, Inc files its 3Q 10Q

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

Nov 29, 2023, 6:13 PM EST - 1 year ago

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Oct 17, 2023, 8:05 AM EDT - 2 years ago

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Oct 12, 2023, 8:05 AM EDT - 2 years ago

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

Oct 4, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

Sep 7, 2023, 9:00 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Sep 6, 2023, 9:45 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Aug 24, 2023, 8:05 AM EDT - 2 years ago

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

Aug 14, 2023, 10:25 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

Aug 3, 2023, 9:05 AM EDT - 2 years ago

Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

Jul 31, 2023, 4:15 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

TRxADE HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc.

Jul 31, 2023, 8:35 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc.

TRxADE HEALTH, Inc. Amends Definitive Merger Agreement with Superlatus, Inc.

Jul 14, 2023, 4:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. Amends Definitive Merger Agreement with Superlatus, Inc.

Superlatus, Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger Agreement to Create a Global Strategic Platform for Food and Healthy Snack Marketplace and Distribution

Jun 30, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger Agreement to Create a Global Strategic Platform for Food and Healthy Snack Marketplace and Distribution

TRxADE HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc. (Correction Notice)

Jun 23, 2023, 4:40 PM EDT - 2 years ago

TRxADE HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc. (Correction Notice)

EAT WELL GROUP TO SELL SAPIENTIA FOR USD $10 MILLION IN NASDAQ MERGER WITH MEDS & SUPERLATUS FOODS

Jun 23, 2023, 3:00 PM EDT - 2 years ago

EAT WELL GROUP TO SELL SAPIENTIA FOR USD $10 MILLION IN NASDAQ MERGER WITH MEDS & SUPERLATUS FOODS

Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform

Jun 23, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform

TRxADE Health, Inc.'s Board of Directors Approves Reverse Stock Split

Jun 21, 2023, 12:36 PM EDT - 2 years ago

TRxADE Health, Inc.'s Board of Directors Approves Reverse Stock Split

TRxADE HEALTH, Inc. (MEDS) Q1 2023 Earnings Call Transcript

May 15, 2023, 10:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. (MEDS) Q1 2023 Earnings Call Transcript

TRxADE HEALTH Reports First Quarter Gross Margin of 69% and Q1 2023 Financial Results

May 15, 2023, 5:00 PM EDT - 2 years ago

TRxADE HEALTH Reports First Quarter Gross Margin of 69% and Q1 2023 Financial Results

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 15th at 6:00 p.m.

May 5, 2023, 4:15 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 15th at 6:00 p.m.

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 8th at 5:00 p.m.

Apr 25, 2023, 12:20 AM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 8th at 5:00 p.m.

TRxADE HEALTH, Inc. (MEDS) Q4 2022 Earnings Call Transcript

Mar 27, 2023, 9:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. (MEDS) Q4 2022 Earnings Call Transcript

Moneymastermind99
Moneymastermind99 Sep. 17 at 2:55 AM
$TGL Update 🚀 Closed strong above key support ~$1.09–1.15, holding trend shift. Next resistance at ~$1.18–1.20, then $1.40–1.50. Breakout on volume could target $2–$2.50+ (52 week high $76.50) Float is tiny (~3.7M), so even small buys/sells move price fast. Indicators (MACD + short MAs) flipping bullish, though long-term trend still weak. Catalysts: AI/cloud expansion via ZCITY, Mezzofy digital coupon partnership, crypto/digital treasury buildout. Risk: If $1.09 breaks, watch $1.00 or lower. Volatility extreme. Similar low-float names: $ADAP $SCNX $IXHL #TGL #Stocks #LowFloat #AI #Momentum #DayTrading
0 · Reply
Bigcat85
Bigcat85 Sep. 17 at 1:29 AM
$SCNX shocker, good news and in the red!
0 · Reply
Jhc1114
Jhc1114 Sep. 17 at 12:43 AM
$SCNX S-3 424B3 FUCK YOU CURRY
0 · Reply
Moneymastermind99
Moneymastermind99 Sep. 16 at 10:03 PM
$TGL Strong Close 🚀 Tiny float = huge volatility. Even small buys/sells move it fast. Closed strong above support ~$1.15 with eyes on $1.40-$1.50 resistance. Breakout on volume could target $2-$3 near term. Risky but explosive setup. 🔥 Similar low-float plays to watch: $ADAP $SCNX $IXHL #TGL #Stocks #LowFloat #Momentum #DayTrading #PennyStocks
0 · Reply
Risktaking
Risktaking Sep. 16 at 6:34 PM
$SCNX Looks more like a squeeze downward. She might be cooked
1 · Reply
Adam_85
Adam_85 Sep. 16 at 5:56 PM
$SCNX Go baby Go
0 · Reply
MakeM0ney_444
MakeM0ney_444 Sep. 16 at 5:23 PM
$SCNX this is being suppressed isn’t it
1 · Reply
MMstockm
MMstockm Sep. 16 at 5:20 PM
$SCNX loading
0 · Reply
Dabstunts
Dabstunts Sep. 16 at 4:58 PM
$SCNX they just stole your shares at .93.....now ready to move! Hold on...
0 · Reply
The_Rocketstock
The_Rocketstock Sep. 16 at 4:57 PM
$SCNX come on,lets do it.
0 · Reply
Dabstunts
Dabstunts Sep. 16 at 4:52 PM
$SCNX ANYONE..........
0 · Reply
Risktaking
Risktaking Sep. 16 at 4:31 PM
$SCNX Does this thing move?
0 · Reply
Dabstunts
Dabstunts Sep. 16 at 3:47 PM
$SCNX Low Float....gonna rip!
0 · Reply
Dabstunts
Dabstunts Sep. 16 at 3:40 PM
$SCNX Look out. Ready to launch! Coiled.....
0 · Reply
JackCampbell
JackCampbell Sep. 16 at 3:03 PM
$SCNX extremely
1 · Reply
MakeM0ney_444
MakeM0ney_444 Sep. 16 at 2:53 PM
$SCNX
0 · Reply
Adam_85
Adam_85 Sep. 16 at 2:20 PM
$SCNX
0 · Reply
MakeM0ney_444
MakeM0ney_444 Sep. 16 at 2:18 PM
$SCNX is this thing coiled and ready to pop?
0 · Reply
Mike93
Mike93 Sep. 16 at 2:03 PM
$SCNX adding here at 1$ chart looks good
0 · Reply
Josh43
Josh43 Sep. 16 at 1:51 PM
$SCNX bought my first 3000 shares today for about a buck looks interesting to me
0 · Reply
Adam_85
Adam_85 Sep. 16 at 1:47 PM
$SCNX lets see some new highs!
0 · Reply
MakeM0ney_444
MakeM0ney_444 Sep. 16 at 1:46 PM
$SCNX nooooooooeeeee
0 · Reply